213 related articles for article (PubMed ID: 11205899)
21. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
22. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
23. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
Lee CT; Lee YJ; Kwon SY; Lee J; Kim KI; Park KH; Kang JH; Yoo CG; Kim YW; Han SK; Chung JK; Shim YS; Curiel DT; Carbone DP
Cancer Res; 2006 Jan; 66(1):372-7. PubMed ID: 16397251
[TBL] [Abstract][Full Text] [Related]
24. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
Su C; Peng L; Sham J; Wang X; Zhang Q; Chua D; Liu C; Cui Z; Xue H; Wu H; Yang Q; Zhang B; Liu X; Wu M; Qian Q
Mol Ther; 2006 May; 13(5):918-27. PubMed ID: 16497559
[TBL] [Abstract][Full Text] [Related]
25. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
27. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT
J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940
[TBL] [Abstract][Full Text] [Related]
28. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.
van Beusechem VW; van den Doel PB; Grill J; Pinedo HM; Gerritsen WR
Cancer Res; 2002 Nov; 62(21):6165-71. PubMed ID: 12414643
[TBL] [Abstract][Full Text] [Related]
29. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic adenoviral therapy in gallbladder carcinoma.
Tekant Y; Davydova J; Ramirez PJ; Curiel DT; Vickers SM; Yamamoto M
Surgery; 2005 May; 137(5):527-35. PubMed ID: 15855925
[TBL] [Abstract][Full Text] [Related]
31. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
32. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
33. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
34. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
35. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
36. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
[TBL] [Abstract][Full Text] [Related]
37. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
38. Engineering regulatory elements for conditionally-replicative adeno-viruses.
Haviv YS; Curiel DT
Curr Gene Ther; 2003 Aug; 3(4):357-85. PubMed ID: 12871022
[TBL] [Abstract][Full Text] [Related]
39. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function.
Fang L; Huang Y; Hu X; Sun L; He X; Hu H; Pu Y; Cao X; Luo H; Pan S; Gu J; Su C
Chem Biol Interact; 2009 Sep; 181(1):1-7. PubMed ID: 19523934
[TBL] [Abstract][Full Text] [Related]
40. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
Sarkioja M; Kanerva A; Salo J; Kangasniemi L; Eriksson M; Raki M; Ranki T; Hakkarainen T; Hemminki A
Cancer; 2006 Oct; 107(7):1578-88. PubMed ID: 16948124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]